Purpose: To evaluate the effectiveness of 12 months of spectacle lens wear incorporating cylindrical annular refractive elements (CARE) in slowing myopia progression compared to single vision (SV) spectacle wear. Methods: In an ongoing 2‐year prospective, double‐masked, multi‐centre clinical trial, 240 Chinese children aged 6–13 years, spherical equivalent refractive error (SE) −0.75 D to −5.00 D were randomised to one of three groups of 80 participants each to wear: SV spectacle lens ( N = 80), CARE spectacles (7 mm central clear zone surrounded by treatment zone incorporating CARE with mean surface power of +4.6 D) and CARE S (9 mm central clear zone surrounded by treatment zone comprising CARE with mean surface power of +3.8 D). Cycloplegic SE and axial length (AL) were measured at 6‐month intervals. Results: Compared to baseline, changes in SE and AL were significantly different between the groups at both 6 and 12 months ( p < 0.001, linear mixed model). Adjusting for site, group, parental myopia and age, at 12 months, the estimated change in SE and AL with 95% CI with SV was −0.65 D (CI: −0.56 to −0.74 D)/0.32 mm (CI: 0.29–0.36 mm). In comparison, the estimated change in SE/AL at 12 months with CARE was −0.35 D (−0.26 to −0.44 D)/0.19 mm (0.15–0.22 mm) and with CARE S was −0.36 D (−0.27 to −0.46 D)/0.21 mm (0.18–0.25 mm) at 12 months. Progression was slower with CARE and CARE S compared to SV ( p < 0.05) but did not differ from each other ( p = 0.793 and 0.336 for SE and AL, respectively). Conclusions: In children with myopia, after 12 months of lens wear, both CARE and CARE S spectacle lenses significantly slowed myopia progression compared to SV lenses.
To evaluate over a 2-year period the efficacy of spectacle lenses incorporating cylindrical annular refractive elements (CARE) in slowing myopia progression compared with single vision (SV) spectacle wear. Double-masked, multicenter, randomized clinical trial. A total of 240 Chinese children aged 6 to 13 years, with a spherical equivalent (SE) refractive error of -0.75 diopters (D) to -5.00 D, were randomized to 1 of 3 groups of SV spectacle lens: CARE spectacles (7-mm central clear zone surrounded by treatment zone incorporating CARE with mean surface power +4.6 D) and CARE S spectacles (9-mm central clear zone surrounded by treatment zone comprising CARE with mean surface power +3.8 D). Cycloplegic SE and axial length (AL) were measured at 6-month intervals. Progression (mean ± SD) in SV-wearing eyes after 24 months of SPL wear was -1.15 ± 0.63 D and 0.59 ± 0.26 mm with SV for SE and AL, respectively. In comparison, myopia progression was significantly slower with both CARE (-0.73 ± 0.63 D/0.40 ± 0.26 mm, P < .0001) and CARE S (-0.80 ± 0.56 D/0.44 ± 0.25 mm, P < .0001). Progression did not differ significantly between CARE lenses. Adjusting for site, group, age, gender, and baseline value at 24 months, CARE showed an absolute difference in SE of 0.44 D (95% CI, 0.21-0.66 D) and CARE S 0.41 D (95% CI, 0.18-0.63D) compared with SV. AL reduction was 0.20 mm (95% CI, 0.10-0.30 mm) with CARE and 0.17 mm (0.07-0.26 mm) with CARE S compared with SV. Over a 2-year period, lenses incorporating CARE significantly slowed myopia progression compared with SV lenses.
13 August 2023 in Ophthalmic and Physiological Optics
Introduction To investigate changes in refractive error in schoolchildren before and during the coronavirus disease 2019 (COVID-19) pandemic. Methods This study included 2792 students, who underwent a 3-year follow-up from 2018 to 2020. All participants underwent yearly noncycloplegic refraction and ocular examinations. Time-related changes in sphere, cylinder, and spherical equivalent (SE) measurements in both genders were analyzed. Results The myopic sphere (− 0.78 ± 1.83 vs. − 1.03 ± 1.91 D; P = 0.025) and SE (− 1.04 ± 1.90 vs. − 1.32 ± 1.99 D; P = 0.015) progressed significantly from 2018 to 2019. Female participants had a significantly greater change in SE than male participants (P < 0.05), and the low hyperopia, emmetropia, and mild myopia groups significantly deteriorated (P < 0.001) from 2018 to 2019. Significant differences in sphere change (− 0.21 ± 0.97 vs. − 0.36 ± 0.96 D; P < 0.001) and SE change (− 0.23 ± 0.99 vs. − 0.38 ± 0.98 D; P < 0.001) were noted between 2019–2018 and 2020–2019, respectively. The respective changes in cylinder were statistically similar (− 0.03 ± 0.53 vs. − 0.05 ± 0.62 D; P = 0.400). Conclusions The refractive status of schoolchildren showed an increasing myopic shift trend before and during the COVID-19 pandemic. The low hyperopia, emmetropia, and mild myopia groups were more sensitive to environmental changes during COVID-19 than before. The myopic shift was greater in female participants than male participants.
Aims To report the 1-year results of the efficacy of a defocus distributed multipoint (DDM) lens in controlling myopia progression in a multicentre, randomised controlled trial. Methods Overall, 168 children aged 6–13 years were recruited and randomly assigned to wear a DDM lens (n=84) or single-vision (SV) lens (n=84) in three centres. Cycloplegic autorefraction (spherical equivalent refraction (SER)) and axial length (AL) were measured. Linear mixed model analysis was performed to compare between-group SER and AL changes. Logistic regression analysis was used to analyse the between-group difference in rapid myopia progression (SER increase≥0.75 D per year or AL growth≥0.40 mm per year). Results After 1 year, mean changes in SER were significantly lower in the DDM group (−0.47±0.37 D) than in the SV group (−0.71±0.42 D) (p<0.001). Similarly, mean changes in AL were significantly lower in the DDM group (0.21±0.17 mm) than in the SV group (0.34±0.16 mm) (p12 hours per day, boys and younger children (6–9 years) with ORs (95% CIs) of 10.82 (3.22 to 36.37), 5.34 (1.93 to 14.78) and 8.73 (2.6 to 29.33), respectively. Conclusions After 1 year, DDM lenses effectively retarded myopia progression in children. Longer daily wearing time of DDM lens improved the efficacy of myopia control. Future long-term studies are needed for validation. Trial registration number NCT05340699.
To evaluate the 12-month myopia control efficacy of an Asymmetric Multi-point Defocus Technique (AMDT) spectacle lens. Double-masked randomized controlled trial. 140 participants completed all visits (mean age, 10.6 ± 1.5 years; 50% female), with SER between -5.00 and -0.75 diopter (D), astigmatism ≤ 1.50 D and anisometropia ≤ 1.50 D. 144 children recruited from two ophthalmic centers aged 8-13 years with myopia of -0.75 D to -5.00 D were randomized (1:1) to wear AMDT or single vision (SVL) spectacle lenses. Cycloplegic spherical equivalent refraction (SER) and axial length (AL) were measured at the baseline, 6-month, and 12-month visits. Adaptation and visual performance questionnaires were administered during the intervention. The SER change after one year was the primary outcome and the change in AL, visual performance, and ocular parameters after one year were defined as secondary outcomes. After 12 months, the SVL group (n = 69) exhibited mean changes in SER and AL of -0.50 ± 0.06 D and 0.32 ± 0.02 mm, respectively, compared to -0.16 ± 0.06 D and 0.17 ± 0.02 mm (both p< 0.001) in the AMDT group (n = 71). Compared with the SVL group, participants in the AMDT group had significantly less myopia progression by 0.39 D in SER (74%) and 0.17mm in AL (51%) after adjustment for baseline age, baseline SER/AL and ophthalmic center. The correlation between younger age and more rapid AL elongation was more pronounced in the SVL group (r = -0.68, p <0.001), compared to the AMDT group (r = -0.37, p = 0.002). 30 (42.2%) participants in the AMDT group displayed no SER progression after 1-year. No serious adverse events or persistent visual discomfort were observed. Compared with SVL, AMDT spectacle lenses significantly reduced SER and AL progression over 1 year, with a favorable safety profile and visual performance. The correlation between age and myopia progression was diminished after AMDT intervention, but not for SVL.